Arabic Arabic English English French French German German
dark

Viva Biotech Announced 2021 Interim Results

Viva Biotech Holdings (1873.HK) announced that during the period ended June 30, 2021 (the “Reporting Period”), revenue of the Group increased significantly to RMB1,026.5 million from RMB197.6 million for the corresponding period last year Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

XPhyto Launches First Commercial Biosensor for Oral Disease

Next Post

CureVac Preclinical Data Demonstrates Significant Reduction of Liver Fibrosis with mRNA Therapeutic

Related Posts
Total
0
Share